Citadel Advisors
ANAB icon

Citadel Advisors’s AnaptysBio ANAB Stock Holding History

Citadel Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$722K Buy
+10,700
New +$649K ﹤0.01% 8998
2026
Q1 		– Sell
-30,400
Closed -$1.47M – 12912
2025
Q4 		$1.47M Buy
30,400
+23,400
+334% +$912K ﹤0.01% 6546
2025
Q3 		$214K Sell
7,000
-12,500
-64% -$287K ﹤0.01% 11123
2025
Q2 		$433K Buy
19,500
+8,600
+79% +$180K ﹤0.01% 8969
2025
Q1 		$203K Sell
10,900
-114,700
-91% -$1.91M ﹤0.01% 10419
2024
Q4 		$1.66M Buy
125,600
+97,600
+349% +$2.36M ﹤0.01% 6007
2024
Q3 		$938K Buy
28,000
+23,800
+567% +$813K ﹤0.01% 6994
2024
Q2 		$105K Buy
4,200
+2,000
+91% +$46.6K ﹤0.01% 10839
2024
Q1 		$49.5K Buy
2,200
+1,600
+267% +$37.9K ﹤0.01% 12178
2023
Q4 		$12.9K Sell
600
-3,900
-87% -$67.3K ﹤0.01% 12960
2023
Q3 		$80.8K Buy
+4,500
New +$85.9K ﹤0.01% 11165
2023
Q2 		– Sell
-300
Closed -$6.53K – 14286
2023
Q1 		$6.53K Sell
300
-1,600
-84% -$38.9K ﹤0.01% 13797
2022
Q4 		$58.9K Buy
+1,900
New +$53.7K ﹤0.01% 11931
2021
Q3 		– Sell
-8,300
Closed -$215K – 13745
2021
Q2 		$215K Sell
8,300
-24,200
-74% -$580K ﹤0.01% 12000
2021
Q1 		$700K Buy
+32,500
New +$820K ﹤0.01% 8944
2020
Q2 		– Sell
-11,000
Closed -$155K – 9716
2020
Q1 		$155K Sell
11,000
-84,900
-89% -$1.29M ﹤0.01% 8258
2019
Q4 		$1.56M Sell
95,900
-27,700
-22% -$655K ﹤0.01% 4818
2019
Q3 		$4.33M Buy
123,600
+101,900
+470% +$4.85M ﹤0.01% 3304
2019
Q2 		$1.22M Buy
21,700
+100
+0.5% +$7.2K ﹤0.01% 5371
2019
Q1 		$1.58M Buy
21,600
+3,600
+20% +$249K ﹤0.01% 4848
2018
Q4 		$1.15M Sell
18,000
-39,200
-69% -$2.92M ﹤0.01% 5098
2018
Q3 		$5.71M Buy
57,200
+36,400
+175% +$3.02M ﹤0.01% 2834
2018
Q2 		$1.48M Sell
20,800
-22,700
-52% -$1.9M ﹤0.01% 4566
2018
Q1 		$4.53M Buy
43,500
+40,300
+1,259% +$4.54M ﹤0.01% 2575
2017
Q4 		$322K Buy
+3,200
New +$236K ﹤0.01% 6347

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Citadel Advisors's ANAB Position: Q2 2026 in Review

Citadel Advisors increased its AnaptysBio (ANAB) stake by 69% in Q2 2026, buying an estimated $9.75M and bringing the position to 394,373 shares worth $26.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Citadel Advisors first reported a position in ANAB in Q3 2017 and has held it in 33 quarters since. The position peaked at $64.8M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Citadel Advisors held 394,373 shares of AnaptysBio worth $26.6M as of Q2 2026.
  • Citadel Advisors bought 160,923 AnaptysBio shares in Q2 2026, an estimated $9.75M.
  • AnaptysBio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2236 holding.
  • Citadel Advisors first reported a position in AnaptysBio in Q3 2017 and has held it in 33 quarters since.
  • Citadel Advisors's AnaptysBio position peaked at $64.8M in Q3 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.